Evaluation of Cardiopulmonary Exercise Test and Echocardiographic Parameters in Patients with Type 2 Diabetes Mellitus

Yıl 2022, Cilt: 9 Sayı: 1, 44 - 48, 29.04.2022

Gamze Aslan , Ömer Yıldız

https://doi.org/10.47572/muskutd.832255

Öz

Cardiopulmonary exercise test (CPET) is generally used as a test to evaluate the responses of the cardiovascular, pulmonary and musculoskeletal systems to exercise. In this study, it was aimed to evaluate the echocardiographic findings with CPET and their relations in Type2 DM patients. CPET and transthoracic echocardiography were performed in all patients. 30 patients with Type2 DM (mean age:44.3±5.6years) and 20 healthy controls (mean age:42.2±3.5 years) were included in the study (p=0.141). Maximal work load (p=0.01), peak VO2 (p=0.002), peak VO2 predicted (p=0.011), E/A (p=0.027) were significantly decreased in the Type2 DM group when compared to the control group, but VE/VCO2 slope (p=0.015) was significantly increased in Type2 DM group. While the peak VO2 was positively correlated with maximal VO2 (r=0.49, p=0.001), maximal work load (r=0.72, p<0.001) and exercise time (r=0.44, p=0.002), left ventricle mass index (LVMI) (r=-0.33, p=0.023), resting systolic blood pressure (r=-0.36, p=0.013), peak systolic blood pressure (r=-0.32, p=0.029) and peak diastolic blood pressure (r=-0.32, p=0.029) showed negative correlations. The linear regression analyzes of LVEF, LVMI and Type2 DM that may affect the peakVO2 levels showed a significant relationship with high levels of peak VO2 and Type2 DM (p=0.017). Peak VO2 in CPET test values were found to be significantly lower in Type2 DM patients compared to the control group in our study. We found out that the presence of Type2 DM could independently affect the peak VO2 value according to linear regression analysis. Prospective randomized controlled studies are needed for the clear determination of this relationship in these patient groups for the evaluation of cardiovascular risks.

Anahtar Kelimeler

Cardiopulmonary Exercise Test, Echocardiography, Exercise Test, Type 2 Diabetes Mellitus

Tip 2 Diyabetes Mellitus’lu Hastalarda Kardiyopulmoner Egzersiz Testi ve Ekokardiyografik Parametrelerin Değerlendirilmesi

Öz

Kardiyopulmoner egzersiz testi (KPET); genellikle kardiyovasküler, pulmoner ve kas-iskelet sistemlerinin egzersize yanıtlarının değerlendirilebildiği bir tetkik olarak kullanılmaktadır. Bu çalışmada, Tip2 DM hastalarında KPET ile ekokardiyografik bulguların ve ilişkilerinin değerlendirilmesi hedeflenmiştir. Tüm hastalara KPET ve transtorasik ekokardiyografi yapıldı. 30 kişi Tip2 DM grubuna (ortalama yaş 44.3±5.6 yıl), 20 sağlıklı kişi (ortalama yaş 42.2±3.5 yıl) ise kontrol grubuna alındı (p=0.141). Maksimal iş yükü (p=0.01), zirve VO2 (p=0.002), zirve VO2 tahmini (p=0.011), E/A (p=0.027) değerleri Tip2 DM grubunda kontrol grubuna göre anlamlı olarak daha düşük, VE/VCO2 eğimi (p=0.015) ise kontrol grubuna göre daha yüksek saptandı. Zirve VO2 değeri ile maksimal VO2 (r=0.49, p=0.001), maksimal iş yükü (r=0.72, p<0.001), egzersiz süresi (r=0.44, p=0.002) pozitif korelasyon gösterirken; sol ventrikül kitle indeksi (SVKİ) (r=-0.33, p=0.023), istirahat sistolik kan basıncı (r=-0.36, p=0.013), zirve sistolik kan basıncı (r=-0.32, p=0.029) ve zirve diastolik kan basıncı (r=-0.32, p=0.029) negatif korelasyon gösterdi. Zirve VO2 değerini etkileyebilecek yaş, SVEF, SVKİ, Tip2 DM varlığı parametrelerinin eklenmesiyle yapılan lineer regresyon analizinde, Tip2 DM varlığının (p=0.017) zirve VO2 değeri ile anlamlı ilişkisi olduğu bulundu. Çalışmamızda, Tip2 DM’li hastalarda kontrol grubuna göre KPET testinde zirve VO2 değerleri anlamlı olarak düşük bulunmuştur. Lineer regresyon analizinde de Tip2 DM varlığının zirve VO2 değerini bağımsız olarak etkileyebileceği yönünde veri elde edilmiştir. Bu hasta grubunda kardiyovasküler riskin belirlenmesinde yol gösterici olabilecek bu ilişkiyi daha net değerlendirmek için prospektif randomize kontrollü çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

Egzersiz Testi, Ekokardiyografi, Kardiyopulmoner Egzersiz Testi, Tip 2 Diabetes Mellitus

Kaynakça

• 1. Force ERST, Palange P, Ward SA, et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J. 2007;29(1):185-209.
• 2. Sue DY, Hansen JE. Normal values in adults during exercise testing. Clin Chest Med. 1984;5(1):89-98.
• 3. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035-8.
• 4. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-35.
• 5. Pitocco D, Fuso L, Conte EG, et al. The diabetic lung--a new target organ? Rev Diabet Stud. 2012;9(1):23-35.
• 6. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2014;37(Supplement 1):81-90.
• 7. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the american society of echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the european society of cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-63.
• 8. Laukkanen JA, Lakka TA, Rauramaa R, et al. Cardiovascular fitness as a predictor of mortality in men. Arch Intern Med. 2001;161(6):825-31.
• 9. Harris G, White R. Exercise stress testing in patients with type 2 diabetes: when are asymptomatic patients screened? Clinical Diabetes. 2007;25:126-30.
• 10. Church TS, LaMonte MJ, Barlow CE, Blair SN. Cardiorespiratory fitness and body mass index as predictors of cardiovascular disease mortality among men with diabetes. Arch Intern Med. 2005;165(18):2114-20.
• 11. Albright A, Franz M, Hornsby G, et al. American college of sports medicine position stand. exercise and type 2 diabetes. Med Sci Sports Exerc. 2000;32(7):1345-60.
• 12. Miki K, Maekura R, Hiraga T, et al. Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir Med. 2003;97(5):482-90.
• 13. Kleber FX, Vietzke G, Wernecke KD, et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation. 2000;101(24):2803-9.
• 14. Ponikowski P, Francis DP, Piepoli MF, et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation. 2001;103(7):967-72.
• 15. Litonjua AA, Lazarus R, Sparrow D, et al. Lung function in type 2 diabetes: the Normative Aging Study. Respir Med. 2005;99(12):1583-90.
• 16. Shah SH, Sonawane P, Nahar P, et al. Pulmonary function tests in type 2 diabetes mellitus and their association with glycemic control and duration of the disease. Lung India. 2013;30(2):108-12.
• 17. Aparna A. Pulmonary function tests in type 2 diabetics and non-diabetic people -a comparative study. J Clin Diagn Res. 2013;7(8):1606-8.